Navigation Links
Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Date:12/9/2008

SEATTLE, Dec. 9 /PRNewswire/ -- Omeros Corporation today announced favorable results from a Phase 1 vehicle-controlled study of OMS201, another of Omeros' PharmacoSurgery(TM) product candidates, for use during urological surgery.

The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic data from this study show that systemic plasma levels of the active agents of OMS201 in patients were minimal and in most cases below the level of quantification. There were no serious adverse events.

"We continue to be encouraged by the progress being made in our OMS201 development program, and the completion of this study represents another successful milestone as we advance our PharmacoSurgery(TM) platform," stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Based on these positive results, we intend to initiate a Phase 1/Phase 2 study evaluating the safety and preliminary efficacy of two higher concentrations of OMS201 in uroendoscopic surgery."

The Phase 1 study was a randomized, double-blind, vehicle-controlled and parallel-assigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros' proprietary PharmacoSurgeryTM platform, is designed for use during urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to standard irrigation solutions in urological surgery, OMS201 is delivered during the operation directly to the surgical site to inhibit surgically induced inflammation, pain and smooth muscle spasm.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros and BlueCrest Announce $20 Million Debt Facility
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. Omeros Appoints David A. Mann to its Board of Directors
4. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
5. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
6. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Elsevier Announces Winners of 3rd Annual Scopus Young Indian Scientist Award
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
10. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
11. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/3/2016)... 3, 2016   ViaCyte, Inc ., a ... pluripotent stem cell-derived islet replacement therapy for the ... today announced that ViaCyte and Janssen Biotech, Inc., ... & Johnson, have agreed to consolidate the assets ... agreement provides ViaCyte with an exclusive license to ...
(Date:2/3/2016)... NEW BRUNSWICK, N.J. , Feb. 3, 2016 ... 30 grants totaling more than $1 million for ... who are working on health-related research that demonstrates ... , this round of funding for the New ... available for faculty members at these educational institutions— ...
(Date:2/3/2016)... MEDFORD, Mass. , Feb. 3, 2016  Silk Therapeutics, ... A2 financing round. Silk Therapeutics has now raised a total ... progress made by the company. The Series A2 round was ... Foxboro, Massachusetts , with participation from new investors Lear ... Sheri and Roy P. Disney ; Richard Sackler ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces the ... Joey Fatone . Las Vegas , where ... --> Las Vegas , where Joey appeared at ... The new video ad was filmed at the Consumer Electronics Show (CES2016) ... Wocket booth to meet and greet fans. --> ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):